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Abstract 21 
Fibrosis is a complication of chronic inflammatory disorders such as 22 
inflammatory bowel disease (IBD), a condition which has limited therapeutic 23 
options and often requires surgical intervention. Pharmacologic inhibition of 24 
oxygen-sensing prolyl hydroxylases (PHD), which confer oxygen-sensitivity 25 
upon the hypoxia inducible factor (HIF) pathway, has recently been shown to 26 
have therapeutic potential in colitis, although the mechanisms involved remain 27 
unclear. Here, we investigated the impact of hydroxylase inhibition on 28 
inflammation-driven fibrosis in a murine colitis model. Mice exposed to dextran 29 
sodium sulfate followed by period of recovery developed intestinal fibrosis 30 
characterized by alterations in the pattern of collagen deposition and infiltration 31 
of activated fibroblasts. Treatment with the hydroxylase inhibitor 32 
dimethyloxalylglycine (DMOG) ameliorated fibrosis. TGF-β1 is a key regulator 33 
of fibrosis which acts through the activation of fibroblasts. Hydroxylase 34 
inhibition reduced TGF-β1-induced expression of fibrotic markers in cultured 35 
fibroblasts suggesting a direct role for hydroxylases in TGF-β1 signalling. This 36 
was at least in part due to inhibition of non-canonical activation of extracellular 37 
signal-regulated kinase (ERK) signalling. In summary, pharmacologic 38 
hydroxylase inhibition ameliorates intestinal fibrosis, through suppression of 39 
TGF-β1-dependent ERK activation in fibroblasts. We hypothesize that in 40 
addition to previously reported immunosupressive effects, hydroxylase 41 
inhibitors independently suppress pro-fibrotic pathways. 42 
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New and noteworthy 43 
Here we show that hydroxylase inhibitors reduce fibrosis associated with 44 
intestinal inflammation in vivo. At the cellular level, our data suggest a new 45 
HIF independent role of hydroxylase inhibition in the regulation of TGF-β1 46 
signalling. These data also suggest that non-canonical ERK signalling pathway 47 
is regulated by hydroxylase inhibition. Together, our results show the 48 
therapeutic potential of hydroxylase inhibitors for the treatment of intestinal 49 
fibrosis. 50 
Keywords  51 
Hypoxia; Inflammatory bowel disease; Intestinal fibrosis; Hydroxylase 52 
inhibition; Transforming growth factor β1 (TGF-β1) signalling. 53 
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Introduction 55 
Intestinal fibrosis is a debilitating complication of inflammatory bowel disease 56 
(IBD)(16, 19, 58). Most approaches to therapeutic intervention in IBD are 57 
focused on the control of inflammation rather than fibrosis(58). However, 58 
surgical intervention is commonly necessary due to the formation of fibrotic 59 
tissue(58, 63). Therefore, there is an unmet clinical need for therapies that 60 
suppress pro-fibrotic pathways in IBD.  61 
Fibrosis occurs as a result of an overactive wound healing response and is 62 
characterized by excessive deposition of extracellular matrix (ECM)(16, 47, 63 
58). Fibrosis is a complication of multiple chronic inflammatory disorders 64 
including chronic kidney disease(12, 55), interstitial lung disease(1, 79) and 65 
chronic liver disease(38, 50) as well as IBD(16, 19, 81). At a cellular level, 66 
fibrosis occurs as the result of the over-activation of fibroblasts and other ECM-67 
producing cells(1, 12, 16, 79). Among the factors regulating fibrosis, 68 
transforming growth factor-β1 (TGF-β1) is the key regulator of healing 69 
responses that is implicated in most fibrotic disorders(10, 16, 19, 38). The 70 
interaction of TGF-β1 with its cognate receptors on fibroblasts activates 71 
canonical (Smad-mediated) and non-canonical (Mitogen Activated Protein 72 
Kinases (MAPK)-mediated) signalling pathways that lead to the differentiation 73 
of fibroblasts into pro-fibrotic myofibroblasts(10). Through these pathways, 74 
TGF-β1 induces the expression of crucial pro-fibrotic genes such as α-smooth 75 
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muscle actin (α-SMA), collagen and matrix metalloproteinases and stimulates 76 
fibroblast migration to wounded tissue.  77 
Hydroxylases are oxygen sensing enzymes which confer hypoxic sensitivity 78 
upon the hypoxia inducible factor (HIF) pathway. Four HIF hydroxylases have 79 
been identified to date. Three of these are prolyl hydroxylases (termed PHD1-3) 80 
which regulate HIF stability, and the fourth is an asparagine hydroxylase, 81 
termed factor inhibiting HIF (FIH), that controls HIF transcriptional activity. 82 
The PHD2 isoform is the main regulator of HIF stability through targeting HIF-83 
alpha subunits for hydroxylation-dependent proteosomal degradation(7). These 84 
enzymes have also been identified as key players in inflammatory responses(13, 85 
20, 53, 61). Hydroxylase inhibitors have recently been found to be well 86 
tolerated in patients in clinical trials for efficacy in anemia(9, 28). These 87 
compounds have also been found to ameliorate inflammation in multiple animal 88 
models of colitis(14, 15, 22, 36, 60, 64). However, it remains unclear whether 89 
the protective effects of these drugs extend to the amelioration of intestinal 90 
fibrosis. Furthermore, it is also unclear if their protective effects in colitis are 91 
dependent on the regulation of HIF or other pathways(36, 60, 61, 64). Moreover 92 
recent studies have highlighted a potentially important role for PHD-2 in the 93 
regulation of wound healing responses(32, 78, 80).  94 
In this study, we investigated the effects of hydroxylase inhibition on the 95 
development of intestinal fibrosis. Developing our understanding of the 96 
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mechanisms underpinning the protective effects of hydroxylase inhibitors in 97 
intestinal inflammatory disease will enhance our understanding of their 98 
therapeutic potential. 99 
  100 
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Materials and methods 101 
1. Animal studies 102 
C57BL/6 mice were obtained from Charles River U.K. Prolyl hydroxylase-2 103 
heterozygous knockout mice (PHD2+/-) of the Swiss129 background were 104 
provided by Professor Martin Schneider (University of Heidelberg, Germany). 105 
These mice have been characterised and used in several previous studies(37, 106 
48). All in vivo experiments were performed in compliance with regulations of 107 
the Irish Department of Health and approved by the University College 108 
Dublin’s animal research ethics committee or approved by the ethical 109 
commission of the local government (No. G263/14) and carried out at the 110 
Interfaculty Biomedical Faculty, University of Heidelberg. All experiments 111 
were carried out according to the federation of laboratory animal Science 112 
association (FELASA) guidelines. Female and male mice (ages 10-12 weeks) 113 
were used. For induction of fibrosis, mice were exposed to 2.5% or 5% DSS 114 
(MP Biomedicals, Solon, OH, U.S.A) in drinking water for five days. On day 6 115 
mice were switched to normal drinking water and allowed to recover for 8 or 14 116 
days as indicated. During this period, mice were treated with 8mg/mouse 117 
DMOG (i.p) every 48 hours.  118 
 119 
 120 
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2. In vitro experiments 121 
Primary human colonic fibroblasts (CCD-18Co) were purchased from the 122 
American Type Culture Collection (ATCC, LGC Standards, Middlesex, UK). 123 
Immortalized mouse embryonic fibroblasts (MEF) were a kind gift from Dr 124 
Alexander Hoffmann (University of California, Los Angeles, U.S.A). Primary 125 
MEF of both wild type (WT) and PHD-2+/- backgrounds were isolated from 126 
murine foetuses of the appropriate background. All cells were grown in 1X 127 
Dulbecco’s Modified Eagle’s Medium (Thermo Fisher Scientific, Waltham, 128 
MA, U.S.A) containing 4.5 g/l glucose and L-glutamine. The medium was 129 
supplemented with 10% foetal bovine serum, 50u/ml penicillin and 50 mg/ml 130 
streptomycin. In the case of primary MEFs, the medium was also supplemented 131 
with 2mM L-glutamine. For CCD-18Co cells, 0.1mM non-essential amino acids 132 
were added. For all experiments, cells were switched to serum free medium 24 133 
hours prior to treatment. All treatments were performed in serum free medium. 134 
Cells were stimulated with TGF-β1 for the indicated time periods to induce 135 
expression of fibrotic markers and activation of TGF-β1-stimulated signalling 136 
pathways. To investigate the effects of hydroxylase inhibition on TGF- β1 137 
mediated responses, cells were treated with DMOG or JNJ1935 for 1 or 8 hours 138 
prior to TGF-β1 stimulation as indicated. Hypoxia was achieved in a hypoxia 139 
chamber (Coy laboratories, Grass Lake, MI, USA). Steady-state atmospheric 140 
levels of oxygen inside the chamber were reduced to 1%, at a temperature of 141 
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37°C with 5% CO₂ (balance N2) in humidified conditions. Media added to cells 142 
during hypoxic exposures was pre-equilibrated to hypoxia overnight. For 143 
studies where the effects of hydroxylase inhibitors were compared to MEK 144 
inhibitors, cells were treated with the MEK inhibitor PD186416 for 1 hour prior 145 
to TGF-β1 stimulation. For studies assessing the involvement of HIF in 146 
hydroxylase inhibitor mediated effects on fibrosis, cell were treated with 147 
Digoxin or Camptothecin and then treated with DMOG prior to TGF-β1 148 
stimulation.  149 
3. Estimation of disease parameters and histologic analysis  150 
Body weight, presence of blood in feces, and stool consistency/diarrhea were 151 
recorded daily for each mouse to determine the disease activity index (DAI). 152 
These parameters were scored as previously described(64). On termination of 153 
the experiments, mice were sacrificed by cervical dislocation and approximately 154 
1cm from the distal colon was collected, fixed in 10% formalin and embedded 155 
in paraffin. 4 μm sections were cut, mounted on slides, deparaffinized with 156 
xylene, and rehydrated in a graded series of alcohols. For assessment of tissue 157 
inflammation, sections were stained using hematoxylin and eosin (H&E). 158 
Images were taken using an Aperio scanscope XT (Aperio technologies, Vista, 159 
CA, U.S.A). Tissue inflammation was assessed in a blinded fashion by 2-3 160 
independent experienced observers and expressed as an average between the 161 
estimations provided. The score was calculated as previously described(61). 162 
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Fibrosis was assessed as changes in the amount and pattern of collagen 163 
deposition in the colonic mucosa and submucosa using Picrosirius red staining 164 
(0.5g of direct red 80 (Sigma) and 0.5g of fast green (Sigma) in 500 ml of 165 
saturated picric acid solution) and images obtained as described above. Tissue 166 
collagen was quantified using ImageJ (National Institutes of Health, Bethesda, 167 
MD) and a quantification method developed in-house. Briefly, images were 168 
separated into different colour channels and the red channel was selected for 169 
quantification of Collagen. From images obtained using double polarized 170 
microscopy, collagen-I was quantified, whereas from images obtained using 171 
transmitted light, the total amount of collagen was quantified. The colour 172 
threshold was adjusted to obtain black and white images, where collagen 173 
structures appeared in black on a white background. A small square fitting the 174 
width of the sub-mucosal area was drawn and the percentage of black vs white 175 
was quantified in 6 random areas of the sub-mucosa for each imaged sample. 176 
Alternatively, the lamina propria was separated using a drawing tool and total 177 
mucosal collagen quantified as the percentage of black over a white 178 
background.   179 
To analyse the presence of activated fibroblasts in the colon, 180 
immunofluorescent staining for α-SMA was performed using 4’, 6-diamidino-2-181 
phenylindol (DAPI) to counterstain nuclei (details on the primary and secondary 182 
antibodies can be found in table 1, antibodies list). Quantification of α-SMA 183 
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was developed using the total percentage of area tool in ImageJ® using a method 184 
similar to that described for collagen quantification. Briefly, images were split 185 
into color channels and the green channel was selected. The threshold of the 186 
signal was adjusted and color filter applied so the green signal appeared as 187 
black versus a white background. The total amount of black signal in the 188 
mucosal area was quantified using ImajeJ. 189 
For assessment of the presence of phospho-ERK positive cells in fibrotic 190 
tissues, immunohistochemistry was performed using a specific phospho-ERK 191 
primary antibody (details can be found in table 1). The procedure was 192 
developed using a Vectastain Elite ABC-kit (Vector Laboratories, CA, U.S.A) 193 
following manufacturer’s instructions with 3, 3’-Diaminobenzidine (DAB) used 194 
as substrate. Haematoxylin was used to counter-stain nuclei.   195 
4. Wound healing assay 196 
 MEF cells were grown to confluence in 6 well plates. Once confluent, cells 197 
were starved overnight in serum free medium. Monolayers were treated with 198 
DMOG for 1 hour. After treatment, monolayers were scratched with a p200 tip 199 
to produce a wound, and stimulated with TGF-beta for 24 hours. Cells were 200 
then fixed in 4% p-formaldehyde and stained for alpha-SMA as described in 201 
the previous section. 202 
 203 
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5. Western blotting 204 
Whole cell protein lysates preparation and western blot analysis were performed 205 
according to previously described methods(15). A full list of the antibodies used 206 
can be found in table 1. 207 
6. Quantitative real time polymerase chain reaction 208 
RNA was isolated using trizol based extraction. Complementary DNA was 209 
synthesized using standard protocols and quantitative real time polymerase 210 
chain reaction carried out as previously described(20). A full list of targets 211 
analysed and primers used can be found in table 2.   212 
7. luciferase reporter studies 213 
All transfections were performed following previously described methods(52). 214 
For the study of the effects of hydroxylase inhibition on TGF-beta mediated 215 
activation of Smad responses, MEF cells were transfected with the luciferase 216 
reporter SBE4-Luc which was a gift from Bert Vogelstein (addgene 217 
plasmid#16495)(75). To validate the specificity of the reporter, MEF were co-218 
transfected with SBE4-Luc and Smad2 or Smad3 overexpression constructs, 219 
and the activation of the luciferase reporter was evaluated. pCMV5B-Flag-220 
Smad3 was a gift from Jeff Wrana (addgene pasmid #11742)(40). pCMV5 221 
Smad2-HA was a gift from Joan Massague (addgene plasmid #14930)(25). 222 
 223 
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8. Statistical analysis 224 
Graph Pad Prism version 5.0 was used for all statistical analysis. One-way 225 
ANOVA followed by a Newman Keuls post-test was used for comparison of 226 
multiple groups. Student’s t-test was used for individual group comparisons. 227 
Differences were considered statistically significant when the p-value was 228 
≤0.05. There was a minimum of 3 experimental replicates per group. 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
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Results 242 
1. DMOG reduces intestinal fibrosis in DSS-induced colitis 243 
Hydroxylase inhibitors have been shown to have beneficial effects in multiple 244 
models of experimental colitis although their effect on colitis-associated fibrosis 245 
remains unknown(15, 60, 64). Figure 1A shows representative images of mouse 246 
colon stained with H&E (reflecting tissue inflammation-upper panels), picro-247 
sirius red (reflecting collagen deposition-middle panels) or with 248 
immunofluorescence staining for α-SMA (reflecting fibrotic fibroblast 249 
infiltration-lower panels). DSS-treatment led to mucosal inflammation, 250 
disruption of intestinal structures and submucosal edema which partially 251 
recovered following 14 days of natural recovery (Figures 1A). Treatment with 252 
the hydroxylase inhibitor DMOG reduced markers of inflammation and 253 
significantly accelerated the recovery of disease activity scores (figures 1A, 1B 254 
and 1C). Inflammation was associated with the development of fibrosis, 255 
reflected by a change in the pattern of collagen deposition characterized 256 
particularly by increased submucosal collagen (Figures 1A and 1D, white 257 
arrows point areas of higher collagen deposition). A similar pattern of collagen 258 
deposition in the submucosa in a model of DSS induced fibrosis has previously 259 
been described by Ding and colleagues(17). Fibrosis was also characterized by 260 
the presence of infiltrating α-SMA positive fibroblasts in the colonic mucosa 261 
(Figures 1A and 1E, white arrows point areas of fibroblast infiltration). Mice 262 
treated with DMOG demonstrated reduced inflammation with normal mucosal 263 
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structures, an absence of inflammatory infiltrates and a reduction in submucosal 264 
edema (figure 1A and 1C). DMOG treatment also reduced and normalized the 265 
pattern of submucosal collagen deposition, and reduced infiltration by α-SMA 266 
positive fibroblasts (Figure 1A, D and E).  267 
2. Heterozygous deficiency of PHD2 is not protective against DSS induced 268 
intestinal fibrosis 269 
PHD2 is the main regulator of HIF-α stability (2, 7, 68). PHD2 has been 270 
previously reported to be involved in the regulation of the wound healing 271 
response(32, 78, 80). To investigate whether the antifibrotic effects of DMOG 272 
in intestinal fibrosis were mediated by regulation of the canonical PHD2/HIF 273 
pathway, we compared the development of fibrosis in WT vs PHD2+/- mice 274 
exposed to DSS and allowed to recover for 8 days. Figure 2A shows 275 
representative images of mouse colon cross-sections stained with H&E, picro-276 
sirius red or immunofluorescence for α-SMA, comparing WT and PHD2+/- 277 
mice. DSS caused colitis in WT mice (Figure 2A, B and D). Furthermore, 278 
intestinal inflammation was accompanied by profound fibrosis with formation 279 
of α-SMA fibroblast aggregates (Figure 2A and 2E) and increased mucosal and 280 
submucosal deposition of collagen (Figure 2A and 2F). As demonstrated 281 
previously, WT mice treated with DMOG had significantly reduced DAI scores 282 
(Figure 2B) and reduced severity of fibrosis with reduced fibroblast infiltration 283 
and mucosal collagen deposition (Figure 2A, 2E and 2F). In contrast to DMOG 284 
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treated mice, PHD2+/- mice were fully susceptible to DSS induced colitis with 285 
severe signs of disease reflected by high DAI scores (Figure 2C), severe 286 
inflammation (Figure 2A and 2D) and significant fibrosis (Figure 2A, 2E and 287 
2F). These results show that reduced activity of PHD2 alone does not 288 
ameliorate intestinal fibrosis, suggesting that the antifibrotic actions of DMOG 289 
are likely independent of the inhibition of PHD2 and canonical activation of the 290 
HIF pathway. 291 
3. Hydroxylase inhibition directly inhibits TGF-β1 induced fibroblast 292 
activation. 293 
In order to investigate whether the effects of hydroxylase inhibition on fibrosis 294 
were due to its anti-inflammatory actions or to direct anti-fibrotic effects on 295 
fibroblasts, we investigated the effects of hydroxylase inhibitors on TGF-β1-296 
induced fibroblast activation. As shown in Figure 3A, human colonic CCD-297 
18Co fibroblasts stimulated with 1ng/ml of TGF-β1 for 48 hours underwent a 298 
phenotypic transformation into myofibroblasts, characterised by increased 299 
expression of α-SMA stress fibres. Moreover, western blot analysis revealed a 300 
TGF-β1 mediated induction of both α-SMA and collagen-1(α) expression 301 
(Figure 3B). Treatment with either DMOG or JNJ1935 prior to TGF-β1 302 
stimulation reduced differentiation of the cells into myofibroblasts as shown by 303 
reduced presence of α-SMA stress fibres (Figure 3C). Moreover, a reduction of 304 
both α-SMA and collagen-1(α)-1 was observed in cells treated with the 305 
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hydroxylase inhibitors prior to TGF-β1 stimulation (Figure 3D-F). Taken 306 
together, these data suggest that the antifibrotic actions of hydroxylase 307 
inhibitors may be due to their ability to block TGF-β mediated fibroblast 308 
activation. Moreover the fact that JNJ1935, which evokes significantly lower 309 
activation of HIF than DMOG, caused an equivalent reduction of fibrotic 310 
markers to DMOG further suggests that the effects of DMOG are HIF 311 
independent(4). 312 
4. Hydroxylase inhibition does not affect activation of the TGF-β-Smad 313 
signalling pathway 314 
To investigate how hydroxylase inhibition suppresses the effects of TGF-β1, we 315 
analysed the effects of hydroxylase inhibitors on activation of the canonical 316 
TGF-Smad signalling pathway. To facilitate transfection studies, mouse 317 
embryonic fibroblasts (MEF) were used in these experiments. DMOG reduced 318 
the number of α-SMA positive MEF that migrated into a wound space under the 319 
influence of TGF-β1 in a wound healing assay, compared to cells that were 320 
stimulated with TGF-β1 in the absence of hydroxylase inhibition (Figure 4A). 321 
This effect correlated with the ability of DMOG to significantly reduce TGF-β1 322 
induced expression of α-SMA mRNA, confirming that hydroxylase inhibitors 323 
exert similar effects on TGF signalling in MEF and indicating that such effects 324 
are also reflected at the transcriptional level (Figure 4B). We next tested the 325 
effect of DMOG on Smad signalling. Stimulation with TGF-β1 induced 326 
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phosphorylation of Smad2 and Smad3 at 30 to 120 minutes (Figure 4C-4E). 327 
Treatment with DMOG failed to reduce Smad2 phosphorylation at any time 328 
point, although it modestly reduced levels of pSmad3 at 2 hours (figure 4C-4E). 329 
The combination of hydroxylase and proteosome inhibition did not further 330 
affect the phosphorylation of Smad2/3, confirming that DMOG does not 331 
enhance pSmad degradation (Figure 4C-4E). To further analyse the effects of 332 
hydroxylase inhibitors on Smad pathway functionality, MEF were transfected 333 
with the Smad luciferase reporter SBE4-Luc. This construct incorporates four 334 
copies of the Smad binding element (SBE) in its promoter. Co-transfection of 335 
MEF with SBE4 and Smad2 or Smad3 overexpression plasmids showed 336 
activation of the reporter as expected (Figure 4F), with Smad3 more active than 337 
Smad2 in this regards in the absence of TGF-β1 (Figure 4F). Similarly, TGF- β1 338 
activated the SBE4-Luc reporter in a time-dependent fashion that was maximal 339 
at 8 hours (Figure 4G). However, DMOG did not reverse the effect of TGF-β1 340 
on Smad-dependent luciferase activity (Figure 4G). Together these results show 341 
that the effects of hydroxylase inhibitors on responses to TGF-β1 are not due to 342 
blockade of the canonical Smad signalling pathway.  343 
5. Hydroxylase inhibitors reduce TGF-β1 dependent activation of the non-344 
canonical extracellular regulated kinase (ERK) signalling pathway 345 
To investigate an alternative explanation for the effects of the hydroxylase 346 
inhibitors on TGF-β1 signalling, we next examined the effects on non-canonical 347 
18 
 
signalling. Amongst MAPK pathways implicated in TGF-β1 responses, c-Jun 348 
N-terminal kinases (JNK) and ERK have been described for their activation in 349 
fibrotic disease and involvement in the expression of fibrotic markers(3, 26, 31, 350 
38, 42, 43, 55, 72). In the present study, areas of the mucosa of both WT and 351 
PHD-2+/- mice where α-SMA positive fibroblasts are concentrated exhibited 352 
increased pERK nuclear staining, confirming the activation of the ERK pathway 353 
in fibrotic colons (Figure 5A). In vitro, DMOG did not affect TGF-β1 induced 354 
phosphorylation of JNK (data not shown). In contrast, DMOG reduced TGF-β1-355 
induced phosphorylation of ERK (pERK) at 8 hours post stimulation (Figure 5B 356 
and 5D). Interestingly, DMOG did not affect the phosphorylation of the 357 
upstream kinase MEK at the same time point, indicating that the kinase cascade 358 
was specifically affected at the level of ERK activation (Figure 5C and 5E). 359 
Phosphorylation of the linker region of Smad2, which is mediated directly by 360 
ERK(11, 29, 69), was also moderately decreased by DMOG further confirming 361 
the effects of DMOG on phosphorylation of ERK (Figure 5B). The hydroxylase 362 
inhibitor JNJ1935 and atmospheric hypoxia were also examined for their effects 363 
on ERK activation. JNJ1935 caused a time-dependent reduction in TGF-β1-364 
induced ERK phosphorylation that was already present at 6 hours and was 365 
profound at 8 hours post TGF stimulation (Figure 5F and 5G). Of note, hypoxia 366 
did not significantly affect the ability of TGF-β1 to activate this kinase cascade 367 
(Figure 5F and 5G). In order to further analyse the mechanism of hydroxylase 368 
inhibitor mediated reduction of ERK phosphorylation, we compared the effect 369 
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of DMOG and JNJ1935 on ERK and MEK phosphorylation to that of the MEK 370 
inhibitor PD184161 (Figure 5H). While DMOG and JNJ1935 reduced ERK 371 
phosphorylation without affecting that of MEK, the reduction of ERK 372 
phosphorylation caused by PD184161 was accompanied by a dramatic increase 373 
in phosphorylated MEK (Figure 5H). Taken together, these results show that 374 
hydroxylase inhibitors modulate TGF-ERK signalling, which is a potential 375 
mechanism whereby they exert anti-fibrotic effects.  376 
6. The antifibrotic effect of hydroxylase inhibitors is independent of HIF 377 
Our previous in vivo studies demonstrated no protective effects of PHD2 378 
deficiency against fibrosis, thus providing evidence that the antifibrotic effects 379 
of DMOG are HIF independent. To further demonstrate this hypothesis, we 380 
compared the response of WT and PHD2+/- MEF to TGF-β1. Heterozygous 381 
deficiency of PHD2 did not block ERK phosphorylation in response to TGF-β1, 382 
nor did it prevent the ability of DMOG or JNJ1935 to reduce levels of pERK 383 
(Figure 6A). Moreover, stimulation of PHD2+/- cells with TGF-β1 caused an 384 
increase in production of α-SMA and CTGF mRNA (Figure 6B and 6C). The 385 
increment was significantly higher than that found in WT cells, but was 386 
nevertheless abrogated when PHD2+/- cells were treated with DMOG (Figure 387 
6B and 6C). Next, we analysed whether reducing HIF in hydroxylase inhibitor 388 
treated cells would affect the ability of the compounds to reduce the expression 389 
of fibrotic markers. Drugs such as Digoxin and Camptothecin have been 390 
20 
 
described as potent HIF inhibitors (8, 46, 76). As has been previously described, 391 
we found treatment with either digoxin or camptothecin to reduce DMOG 392 
mediated HIF-1α protein stabilization in MEF (data not shown). However, this 393 
reduction of HIF did not affect the ability of DMOG to reduce the expression of 394 
Acta2 (α-SMA) or Ctgf RNA (Figure 6D and 6E). Together these data suggest 395 
that the antifibrotic effects of hydroxylase inhibitors are independent of HIF.  396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
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Discussion 408 
Hydroxylase inhibitors have recently been shown in clinical trials for anemia to 409 
be well tolerated by patients and therefore represent a potentially important new 410 
class of therapeutic agents(9, 28). We and others have previously demonstrated 411 
protective effects of these reagents in multiple models of murine colitis. 412 
Therefore, the potential for repurposing hydroxylase inhibitors for the treatment 413 
of colitis is a realistic possibility. Here, we investigated whether the beneficial 414 
effects of hydroxylase inhibition in intestinal inflammation extend to 415 
inflammation-associated fibrosis, using the DSS-induced murine colitis model. 416 
We show that treatment with the pan-hydroxylase inhibitor DMOG during the 417 
post-DSS recovery period reduces intestinal fibrosis in addition to its known 418 
anti-inflammatory effects. We also show that hydroxylase inhibitors are able to 419 
block TGF-β1 mediated activation of intestinal fibroblasts as well as MEF, and 420 
that they do so at least in part via a HIF-independent manner. At the molecular 421 
level, the inhibitors reduce TGF-β1 mediated activation of the ERK signalling 422 
pathway, thus providing mechanistic insight into the anti-fibrotic actions of 423 
these compounds.    424 
The DSS model of colitis has been used to investigate intestinal fibrosis by 425 
allowing long recovery periods after exposure to DSS(63, 71). Another 426 
approach to the DSS colitis model often used to investigate fibrosis is the so 427 
called multicycle DSS model, where the animals are exposed to multiple cycles 428 
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of DSS followed by one week recovery periods. In a study comparing the 429 
different approaches, Ding et al showed the presence of fibrosis already after 430 
the first DSS cycle of DSS and highlighted that C57BL6 mice do not show 431 
mucosal healing after DSS and progress towards chronic colitis(17). Moreover, 432 
the notion that fibrosis is also a common complication in ulcerative colitis 433 
further validates the potential for the DSS recovery model of colitis as a model 434 
for the study of intestinal fibrosis(23). As previously described, our results show 435 
that mice allowed to recover after exposure to DSS have evident signs of 436 
inflammation and fibrosis even 8 or 14 days after DSS exposure. We also noted 437 
that there are differences in disease progression between the different strains of 438 
mice used. C57BL6 were susceptible to a lower dose of DSS and rapidly 439 
developed colitis showing signs of disease already during the DSS exposure 440 
period. In contrast, Swiss 129 mice did not show signs of disease initially, even 441 
if exposed to a higher dose of DSS. However, this mice developed clear signs of 442 
colitis after the DSS period and progressed towards more severe colitis and 443 
fibrosis. In our studies, treatment of mice with DMOG during the post-DSS 444 
recovery period reduced fibrosis as shown by the reduced presence of mucosal 445 
α-SMA positive fibroblasts and reduced sub-mucosal collagen deposition. 446 
These effects were associated with reduced inflammation, showing that 447 
hydroxylase inhibitors might prove beneficial if used as treatments in 448 
established colitis. Of note, a number of recent studies have indicated that the 449 
inhibition of PHD2 positively regulates healing responses, supporting the 450 
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hypothesis that hydroxylases might be novel targets for the modulation of 451 
wound healing and therefore, fibrosis(32, 78, 80). In our studies, however, 452 
PHD2+/- mice were not protected against chronic inflammation or fibrosis 453 
induced by DSS. Furthermore, PHD2+/- MEF did not demonstrate reduced 454 
sensitivity to TGF-β1 stimulation compared to WT, suggesting that the 455 
beneficial effects of hydroxylase inhibitors in wild-type mice are likely 456 
independent of the PHD2/HIF axis. This HIF independent mechanism is also 457 
supported by the antifibrotic effects obtained with JNJ1935, a drug used at a 458 
concentration that does not inhibit FIH and thus, does not strongly activate HIF. 459 
We further tested the involvement of HIF in hydroxylase inhibitor anti-fibrotic 460 
actions by inhibiting HIF stabilization in DMOG treated cells. As previously 461 
demonstrated, digoxin and camptothecin reduced HIF-1α in DMOG treated 462 
cells(8, 46, 76). However, this did not affect the ability of DMOG to reduce the 463 
expression of α-SMA and CTGF in TGF-β1 stimulated cells. This provided 464 
further evidence that the anti-fibrotic action of hydroxylase inhibitors is HIF 465 
independent. 466 
Fibrosis results from overactive wound healing and is mainly attributed to the 467 
profibrogenic factor TGF-β1(16, 42, 49, 67). In our studies, hydroxylase 468 
inhibitors demonstrated specific anti-fibrotic actions by targeting the ability of 469 
TGF-β1 to up-regulate the production of various key fibrosis markers in 470 
cultures of human colonic fibroblasts and MEF. However, DMOG failed to 471 
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block the phosphorylation of Smad2/3 or the activation of a Smad luciferase 472 
reporter in response to TGF-β1. Rather, hydroxylase inhibitors reduced TGF-β1 473 
mediated activation of the ERK signalling pathway, which has been shown to 474 
play important roles in fibrosis(31, 42, 55) and which we found to be active in 475 
areas of intestinal fibrosis. Thus, we purpose that hydroxylase inhibitors target 476 
the activation of the non-canonical TGF-ERK signaling pathway to cause the 477 
inactivation of the ERK mediated fibrotic response (Figure 7). Together, these 478 
results indicate that hydroxylase inhibitors, in addition to their previously 479 
described anti-inflammatory effects, have beneficial effects against intestinal 480 
fibrosis at least in part through inhibition of the TGF-ERK signaling pathway. 481 
Of note, the inhibitory effects of hydroxylase inhibitors on ERK 482 
phosphorylation were not seen for its upstream kinase MEK. Indeed, 483 
comparison between hydroxylase inhibitors and a MEK inhibitor suggested a 484 
different mechanism for the inhibition of ERK phosphorylation between the two 485 
types of drugs. While MEK inhibitors reduced ERK phosphorylation but 486 
induced a higher level of phosphoMEK, hydroxylase inhibitors reduced 487 
phosphoERK but did not affect phosphoMEK. In order to gain further insights 488 
to the possible mechanism of this PHD inhibitor mediated regulation of ERK 489 
phosphorylation, we hypothesised that PHD inhibitors could upregulate dual 490 
specificity phosphatases (DUSP). DUSP are known to inactivate MAPK and 491 
have been shown to be regulated by hypoxia in multiple studies(5, 35, 41, 54, 492 
56, 66). Hydroxylase inhibition did not increase the expression of DUSPs 493 
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investigated (data not shown). Furthermore, our results are in line with recently 494 
published reports showing beneficial effects of hydroxylase inhibitors in 495 
fibrosis(34, 57, 62, 73, 77). Of note, previous studies have described deleterious 496 
effects for HIF activation in fibrotic pathologies(27, 70). The current study is 497 
not in contradiction with this possibility, as we show that the intestinal 498 
antifibrotic actions of hydroxylase inhibitors are HIF-independent.  499 
The ability of hydroxylase inhibitors to regulate the stability of HIF-α subunits 500 
may have not only beneficial effects, but also potential adverse effects. A 501 
widely discussed side effect of hydroxylase inhibitors is the activation of HIF-502 
dependent EPO production(6, 30, 33), which is seen as an important limitation 503 
to the use of these drugs. However, this ability to increase EPO is currently 504 
being investigated as a therapy for anemia(6, 9, 28). In IBD, anemia is one of 505 
the most common extraintestinal symptoms and it is estimated that one third of 506 
IBD patients suffer from anemia(21). Moreover, anemia is reportedly predictive 507 
of severe and disabling progression in IBD(39). Therefore, the activation of 508 
EPO production with hydroxylase inhibition could be a secondary beneficial 509 
effect in IBD patients where fibrosis and anemia are often co-incidental 510 
outcomes. On the other hand, the use of targeted release forms that allow 511 
specific local delivery of hydroxylase inhibitors to the colon could minimize 512 
systemic exposure. In recent work, we demonstrated that the use of DMOG 513 
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mini-spheres formulated to target delivery to the colon achieved anti-514 
inflammatory effects while minimizing systemic side effects(65).  515 
IBD, including Crohn’s disease (CD) and ulcerative colitis (UC), is increasing 516 
in prevalence, especially in developed countries(45, 51). Advanced stages of 517 
IBD are often associated with excessive wound healing causing fibrosis and 518 
tissue scarring. While much IBD research seeks to unravel the early causes of 519 
pathology, less attention has been paid to long-term complications. Despite the 520 
advances achieved in the treatment of IBD with novel therapies such as anti-521 
TNF-α antibodies that help to maintain remission(14, 44), IBD is still in need of 522 
improved therapeutic approaches. Intestinal fibrosis is a major indication for 523 
surgery in IBD as 75-80% of CD patients are estimated to require surgical 524 
intervention due to the formation of fibrotic scars leading to intestinal 525 
obstructions(47, 59, 63). Further, the importance of fibrosis in a number of other 526 
chronic inflammatory diseases such as chronic kidney disease or interstitial 527 
pulmonary fibrosis(16, 18, 24, 59, 74) and the lack of effective means to limit 528 
progression towards fibrosis suggest that treatments which target fibrotic 529 
disease may represent an important therapeutic advance. We have shown that 530 
hydroxylase inhibitors have promising anti-fibrotic effects, potentially due to 531 
their actions on the non-canonical TGF-ERK signalling pathway. 532 
 533 
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Tables 837 
 838 
Target Supplier Code 
α-SMA Abcam Ab7817 
Collagen-1(α)-1 Santa Cruz Biotechnology sc-8784 
HIF-1α BD Transduction Laboratories #610958 
HIF-1α (clone 
H1a67) 
Merck Millipore MAB5382 
pSmad2 
(carboxyterminal) 
Merk Millipore AB3849 
pSmad2 (linker) Cell Signalling Technology #3104 
pSmad3 Cell Signalling Technology #9520 
TotalSmad2  Cell Signalling Technology #3103 
TotalSmad3 Cell Signalling Technology #9513 
pERK Santa Cruz Biotechnology sc-7383 
TotalERK Cell Signalling Technology #9102 
Alexa fluor 488 
(anti-mouse) 
Thermo Fisher Scientific A-21202 
 839 
 840 
Target Sequence Chemistry Source 
m-α-SMA 
(Acta2) 
5’-TGCTGTCCCTCTATGCCTCT-3’, 
sense 
  
 5’-GCAGGGCATAGCCCTCATAG-3’, 
antisense 
Sybr green Self-designed 
Ctgf Commercially available Taqman probe Taqman Applied 
Biosystems 
Eukaryotic 
18S rRNA 
Commercially available Taqman probe Taqman Applied 
Biosystems 
 841 
 842 
 843 
 844 
 845 
 846 
 847 
 848 
Table 1. Antibodies list. List of antibodies used for immunostaining and 
western blot protein analysis.  
Table 2. Primer list. List of target genes analysed and the complementary primers used for 
qRT-PCR. The list includes the source of the primers. 
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Figure legends 849 
Figure 1. DMOG reduces fibrosis in DSS induced colitis. A, representative images of mouse colon 850 
stained with hematoxylin and eosin (H&E), Picrosirius red imaged with double polarized light 851 
(collagen) and immunofluorescence histochemistry (α-SMA). White arrows point areas of major 852 
collagen accumulation or α-SMA positive infiltrates. Quantification of disease activity index (DAI) 853 
(B), assessment of tissue inflammation (C), submucosal collagen deposition (D) and α-SMA positive 854 
infiltration (E). n=4, * p≤0.05; ** p≤0.01; *** p≤0.001. 855 
Figure 2. Heterozygous deficiency of PHD2 does not protect against intestinal fibrosis in DSS-856 
induced colitis. A, representative images of mouse colon from WT and PHD2+/- mice stained with 857 
H&E, Picrosirius red imaged with transmited light (collagen) and immunofluorescence histochemistry 858 
(α-SMA). Quantification of disease activity index (DAI) in WT mice comparing natural recovery to 859 
IP DMOG treatment (B); Quantification of DAI comparing natural recovery between WT and 860 
PHD2+/- mice (C); Assessment of tissue inflammation (D); Quantification of α-SMA positive 861 
staining (E); Quantification of percentage of mucosal collagen (F). n≥3, * p≤0.05; ** p≤0.01; *** 862 
p≤0.001. 863 
Figure 3. Hydroxylase inhibition reduces TGF-β1 induced human colonic fibroblast 864 
activation. A, representative images of CCD-18Co cells stimulated with 1ng/ml TGF-β1 and 865 
stained for α-SMA using immunofluorescence histochemistry with DAPI as a nuclear 866 
counter-stain (n=2). B, representative western blot of α-SMA and collagen-1(α)-1 in CCD-867 
18Co cells stimulated with 1ng/ml TGF-β1 (n=3); C, representative images of CCD-18Co 868 
stimulated with 1ng/ml TGF-β1 and treated with 1mM DMOG or 100μM JNJ1935, stained 869 
for α-SMA using immunofluorescence histochemistry with DAPI as a nuclear counter-stain 870 
(n=3). D, representative western blot of α-SMA and collagen-1(α)-1 in CCD-18Co cells 871 
treated with 1mM DMOG or 100μM JNJ1935 and stimulated with 1ng/ml of TGF-β1 for 48 872 
hours (n=10). E, densitometry of α-SMA in CCD18Co treated as described in D (n=10). F, 873 
densitometry of collagen-1α in CCD18Co cells treated as described in D (n=10). 874 
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 875 
Figure 4. Hydroxylase inhibition does not affect TGF-β1 induced Smad activation. A, 876 
representative  images of MEF monolayers, treated with 1mM DMOG for 1 hour, wounded 877 
and then stimulated for 24 hours with 10ng/ml TGF-β1, stained for α-SMA using 878 
immunofluorescence histochemistry with DAPI as a nuclear counter-stain (n=4). B, qRT-879 
PCR of α-SMA in MEF stimulated with 1ng/ml TGF-β1 and treated with 1mM DMOG 880 
(n=3); C, representative western blot of pSmad2, pSmad3, TotalSmad2, TotalSmad3, HIF-1α 881 
and β-Actin in MEF stimulated with 1ng/ml TGF-β1 for 1/2h or 1h or 2h and treated with 882 
1mM DMOG for 1h +/- 1/2h 10nM MG132 pre-treatment (n=6); D, densitometry of pSmad2 883 
(n=6); E, densitometry of pSmad 3 (n=6). F, luciferase production in MEF transfected with 884 
SBE4-Luc and co-transfected with pCMV5B-Smad3-flag or pCMV5-Smad2-HA (n=4); G, 885 
luciferase production in MEF transfected with SBE4-Luc and stimulated with 1ng/ml TGF-886 
β1 and treated with 1mM DMOG (n=4). * p≤0.05; ** p≤0.01; *** p≤0.001.  887 
Figure 5. Hydroxylase inhibition reduces TGF-β1 induced ERK activation. A, representative images 888 
of mouse colon cross-sections stained for α-SMA using immunofluorescence histochemistry and 889 
stained for phospho-ERK (pERK) using immunohistochemistry (n≥3). Red arrows point areas of 890 
abundant pERK positive cells, which are often coincident to areas where activated fibroblasts 891 
accumulate. B, representative western blot of pERK, TotalERK, pSmad2 linker, TotalSmad2 and β-892 
Actin in MEF stimulated with 1ng/ml TGF-β1 and treated with 1mM DMOG (n=6); C, 893 
representative western blot of pMEK and β-Actin in MEF stimulated with 1ng/ml TGF-β1 and 894 
treated with 1mM DMOG (n=5). D, densitometry for pERK of the western blots described in B 895 
(n=6); E, densitometry for pMEK of the western blots described in C (n=5). F, representative 896 
western blot of pERK, TotalERK, pMEK, TotalMEK and β-Actin in MEF stimulated with 1ng/ml 897 
TGF-β1 and treated with 100μM JNJ1935 or 1% oxygen (n≥3); G, densitometry for pERK of the 898 
western blots described in F; H, representative western blot of pSmad2 linker, pERK, pMEK and β-899 
Actin in MEF treated with 1mM DMOG or 100μM JNJ1935 or 0.3mM PD184161 and stimulated 900 
with 1ng/ml of TGF-β1 (n=4). * p≤0.05; ** p≤0.01. 901 
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Figure 6. The anti-fibrotic effect of hydroxylase inhibitors is HIF independent. A, representative 902 
western blot of pERK, TotalERK and β-Actin in WT vs PHD2+/- MEF stimulated with 1ng/ml TGF-903 
β1 and treated with 1mM DMOG or 100μM JNJ1935 (n=4); qRT-PCR of α-SMA (B) and CTGF (C) 904 
in WT vs PHD2+/- MEF stimulated with 1ng/ml TGF-β1 and treated with 1mM DMOG (n≥3). 905 
Quantitative real time PCR of α-SMA (D) or CTGF (E) in MEF pre-treated with 100μM digoxin or 906 
2μM camptothecin for 30 minutes, then with 1mM DMOG for 1 hour and then stimulated with 907 
1ng/ml TGF-β1 for 8 hours (n≥3).  * p≤0.05; ** p≤0.01. 908 
Figure 7. Purposed mechanism for hydroxylate inhibitor mediated anti-fibrotic actions. Upper panel 909 
displays the combination of TGF-β1 activated Smad dependent (canonical) and non-canonical (ERK 910 
dependent) signaling pathways. Lower panel shows our purposed model for hydroxylase inhibition 911 
antifibrotic action. Pharmacologic inhibition of oxygen sensing hydroxylases mediates the long term 912 
dephosphorylation of the non-canonical TGF-ERK signaling pathway and reduces the crosstalk 913 
between ERK and Smad pathways. This causes a reduction of the TGF mediated fibroblast activation 914 
and ameliorates fibrosis in a mouse model of colitis.    915 
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